Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial

View Full Paper
Ask AI
Bookmark
Share

Authors

JKJulia KeatingBFBenjamin FrostYFYael Flamand

Discussion

Loading...

Member takes

Overview

Phase I trial shows high remission rates in relapsed ALL and lymphoblastic lymphoma patients, indicating venetoclax with inotuzumab may enhance outcomes.

Key Points

  • A complete remission rate of 95.5% was achieved, with 100% in ALL patients and 85.7% in lymphoblastic lymphoma patients.
  • Patients received up to 5 cycles of treatment, with median time to hematologic recovery of 26 days after induction.
  • This is a phase I trial examining the combination treatment of venetoclax and inotuzumab ozogamicin in adults with relapsed and refractory ALL.
  • The results suggest that the combination therapy may produce favorable outcomes including a durable remission.

Cite This Study

Keating et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d401https://doi.org/10.1182/blood-2025-645
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Molecular and functional determinants of response to venetoclax and inotuzumab ozogamicin in CD22-positive ALL2025
  2. 2Efficacy and safety of inotuzumab ozogamicin combined with venetoclax and dexamethasone in relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)2025 · 1 citations
  3. 3Phase II Results of ECOG-ACRIN EA9152: A multicenter study of liposomal vincristine (L-VCR) or vincristine sulfate (VCR) and venetoclax (VEN) in relapsed or refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL)2025
  4. 4Venetoclax-based therapies in patients with Relapsed/Refractory T-cell prolymphocytic leukemia2025
  5. 5Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial2025 · 4 citations